Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer

Eva Rabing Brix Petersen, Patricia Diana Sørensen, Erik Hugger Jakobsen, Jonna Skov Madsen, Ivan Brandslund

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Serum HER2 (S-HER2) was approved in 2003 by the US Food and Drug Administration (FDA) for monitoring trastuzumab treatment in tissue HER2 positive breast cancer patients. Information of the value of S-HER2 is scarce. We hypothesised that S-HER2 would reflect the clinical effect of trastuzumab.
OriginalsprogEngelsk
TidsskriftClinical Chemistry and Laboratory Medicine
Vol/bind51
Udgave nummer7
Sider (fra-til)1483-92
Antal sider10
ISSN1434-6621
DOI
StatusUdgivet - jul. 2013

Fingeraftryk Dyk ned i forskningsemnerne om 'Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer'. Sammen danner de et unikt fingeraftryk.

  • Citationsformater